Trial
NCT04334174
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Kansas Medical Center
Collaborators
Seagen Inc.
Condition
T Cell Lymphoma
Intervention
Brentuximab Vedotin
Why stopped
accrual not met
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-03